Correction for O’Donnell et al., Stroke 39 (5) 1638-1646.

This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions

(Stroke. 2008;39:e147.)
© 2008 American Heart Association, Inc.

Correction

In the article entitled "Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review" by O’Donnell et al,¹ the authors report two errors. First, in Table 3, under Cilostazol’s Serious Vascular Event Risk Reduction (95% CI) column, the values should be "(0.41–0.91)" instead of "(0.41–0.01)." Second, on page 1641, the reference number of the "Efficacy" category under the "Cilostazol Versus Control" Section should be "41" instead of "42."

The authors regret these errors.

The corrected version can be viewed online at http://stroke.ahajournals.org.

¹[Correction for Vol 39, Number 5, May 2008. Pages 1638–1646.]

This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions